RxSight earnings release, May 6, 2026
RXSIGHT, INC. REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES FULL-YEAR SALES OUTLOOK
Aliso Viejo, Calif. – May 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026.
Strategic Highlights and Recent Developments
• Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units
• 20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units
• Robust clinical data presented at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustability
• Recent regulatory approval in New Zealand furthering the company’s international footprint and global market opportunity
• 2026 sales and gross margin guidance unchanged; operating expense expected to be at high end of previous range reflecting targeted investments in strategic growth initiatives
“
We are encouraged by the stabilizing business trends and the initial progress from our ongoing commercial initiatives,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “As we continue to refine these efforts, investing in both our team and our pipeline, we are confident that we can continue to build momentum across the company and reach the full potential of our technology for patients and practices.”
First Quarter Financial Results
In the first quarter of 2026, the company reported sales of $30.9 million, down 18.5% compared to the prior year, largely reflecting lower LDD unit volumes, consistent with expectations. LAL procedures decreased 0.4% year over year.
First quarter gross profit margin of 76.1% increased from 74.8% in the prior
‑ year period, primarily driven by a favorable shift in product mix toward LAL sales.
Total operating expenses were $41.3 million versus $39.0 million in the year-ago period. The increase was primarily driven by the continued expansion of our global commercial and support teams.
In the first quarter of 2026, the company reported a net loss of $(15.9) million, or $(0.38) per basic and diluted share, compared to a net loss of $(8.2) million, or $(0.20) per basic and diluted share in the first quarter of 2025. Adjusted net loss in the first quarter of 2026 was $(7.9) million, or $(0.19) per basic and diluted share, compared to an adjusted net loss of $(1.1) million, or $(0.03) per basic and diluted share in the first quarter of 2025.
As of March 31, 2026, cash, cash equivalents and short-term investments totaled $217.9 million.
2026 ASCRS Highlights
At the recent ASCRS annual meeting, RxSight technology was featured across multiple scientific presentations addressing refractive accuracy, complex cases and evolving treatment strategies. This rapidly expanding body of clinical evidence highlighted both the versatility and impact of adjustability. In addition, the conference included presentations by Dr. Szabo, who reported binocular LAL outcomes in which 93.1% of patients achieved simultaneous 20/20 or better distance and J1 or better near, as well as a meta-analysis by Dr. Rabinovitch, demonstrating pooled accuracy with the LAL was 91.2% within 0.50 diopters of target refraction.
2026 Guidance
The company’s 2026 financial guidance is as follows:
• Revenue of $120 to $135 million, in-line with previous guidance
• Gross margin of 70% to 72%, in-line with previous guidance
• Operating expenses expected to be at the high-end of previous $150 to $160 million range
• Non-cash stock-based compensation expense of $30 to $32 million, in-line with previous guidance
Conference Call
On Wednesday, May 6, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its first quarter 2026 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/.
An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL/LAL+, collectively the “LAL”), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Financial statements
Income Statement
Three Months Ended March 31, — (In thousands, except share and per share amounts)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Sales | 30,893 | 37,895 | |
| Cost of sales | 7,395 | 9,566 | |
| Gross profit | 23,498 | 28,329 | |
| Operating expenses: | Selling, general and administrative | 31,855 | 28,636 |
| Operating expenses: | Research and development | 9,472 | 10,367 |
| Operating expenses: | Total operating expenses | 41,327 | 39,003 |
| Operating expenses: | Loss from operations | -17,829 | -10,674 |
| Other income (expense), net: | Interest expense | -3 | -6 |
| Other income (expense), net: | Interest and other income | 1,954 | 2,508 |
| Other income (expense), net: | Loss before income taxes | -15,878 | -8,172 |
| Other income (expense), net: | Income tax expense | 6 | 18 |
| Other income (expense), net: | Net loss | -15,884 | -8,190 |
| Other comprehensive loss | Unrealized loss on short-term investments | -120 | -157 |
| Other comprehensive loss | Foreign currency translation gain | 6 | |
| Other comprehensive loss | Total other comprehensive loss | -120 | -151 |
| Other comprehensive loss | Comprehensive loss | -16,004 | -8,341 |
| Net loss per share: | Basic & diluted | -0.38 | -0.2 |
| Weighted-average shares used in computing net loss per share: | Attributable to common stock, basic & diluted | 41,306,110 | 40,509,646 |
Income Statement
Three months ended March 31,
| Three months ended March 31, – 2026 | Three months ended March 31, – 2025 | ||
|---|---|---|---|
| Numerator: | Net loss available to stockholders, basic and diluted | -15,884 | -8,190 |
| Add: | Stock-based compensation | 7,945 | 7,140 |
| Add: | Adjusted net loss available to common stockholders, basic and diluted: | -7,939 | -1,050 |
| Denominator: | Weighted-average shares outstanding, basic and diluted | 41,306,110 | 40,509,646 |
| Denominator: | Adjusted net loss per share, basic and diluted | -0.19 | -0.03 |
Balance Sheet
December 31, — (In thousands, except share and per share amounts)
| March 31, – 2026 – (Unaudited) | December 31, – 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 17,573 | 19,949 |
| Current assets: | Short-term investments | 200,307 | 208,179 |
| Current assets: | Accounts receivable, net | 22,443 | 23,383 |
| Current assets: | Inventories, net | 34,869 | 31,559 |
| Current assets: | Prepaid and other current assets | 4,032 | 4,389 |
| Current assets: | Total current assets | 279,225 | 287,459 |
| Current assets: | Property and equipment, net | 13,232 | 13,056 |
| Current assets: | Operating leases right-of-use assets | 9,760 | 9,959 |
| Current assets: | Restricted cash | 750 | 750 |
| Current assets: | Other assets | 1,026 | 590 |
| Current assets: | Total assets | 303,993 | 311,814 |
| Current liabilities: | Accounts payable | 7,124 | 5,296 |
| Current liabilities: | Accrued expenses and other current liabilities | 18,748 | 19,795 |
| Current liabilities: | Lease liabilities | 1,504 | 1,162 |
| Current liabilities: | Total current liabilities | 27,376 | 26,253 |
| Current liabilities: | Long-term lease liabilities | 9,322 | 9,878 |
| Current liabilities: | Total liabilities | 36,698 | 36,131 |
| Stockholders' equity: | Common stock, $0.001 par value, 900,000,000 shares authorized, 41,384,120 shares issued and outstanding as of March 31, 2026 and 41,242,005 shares issued and outstanding as of December 31, 2025 | 41 | 41 |
| Stockholders' equity: | Additional paid-in capital | 944,244 | 936,628 |
| Stockholders' equity: | Accumulated other comprehensive (loss) income | -67 | 53 |
| Stockholders' equity: | Accumulated deficit | -676,923 | -661,039 |
| Stockholders' equity: | Total stockholders' equity | 267,295 | 275,683 |
| Stockholders' equity: | Total liabilities and stockholders' equity | 303,993 | 311,814 |
Full release
Forward-Looking Statements
This press release contains forward-looking statements, including: including statements regarding the company’s expectations related to stabilizing business trends; the initial progress from its ongoing... (truncated)inology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the three months ended March 31, 2026, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
RxSight, Inc., the RxSight Light Adjustable Lens LAL, LAL+, and LDD are trademarks of RxSight, Inc.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations omoravcevic@rxsight.com